Dosage Charts Calculator Blends & Stacks Learn Blog Peptides
Open Calculator
Blog  ›  PT-141 vs Melanotan I: Simple Research Comparison Guide

PT-141 vs Melanotan I: Simple Research Comparison Guide

Jun 11, 2026 4 min Other
TL;DR
PT-141 (bremelanotide) is a melanocortin peptide studied for sexual dysfunction, while Melanotan I is researched for skin tanning and pigmentation. They work through overlapping receptors but have distinct dosing protocols and research histories. This guide helps you decide which peptide's literature is worth exploring for your curiosity.

Same Family, Different Jobs

Both peptides come from the same scientific neighborhood: the melanocortin system. Think of melanocortins as a set of chemical signals that tell your body to do things like tan your skin, regulate appetite, or trigger sexual arousal. Your body makes its own version, called alpha-MSH. Both PT-141 and Melanotan I are lab-made relatives of that natural molecule.[6]

But being cousins doesn't mean doing the same work. Researchers have pointed these two peptides in very different directions.

What Is PT-141?

PT-141 is the research name for bremelanotide. It is a cyclic peptide — imagine a chain of amino acids bent into a ring shape. That ring makes it more stable in the body than earlier melanocortin molecules.[1]

Scientists at Palatin Technologies developed it primarily to study sexual dysfunction — both erectile dysfunction in men and low sexual desire in women.[1] It works mainly by acting on receptors in the brain, not by increasing blood flow the way older drugs do. That was a big deal in early research.[6] It went through Phase IIb trials for erectile dysfunction and later entered Phase III planning.[1]

What Is Melanotan I?

Melanotan I is a linear peptide — that same chain of amino acids, but left straight rather than curled into a ring. It was designed to stimulate melanin production, the pigment that gives skin its color and provides some protection from UV radiation.[6]

The idea was compelling: could you give someone a protective tan without hours in the sun? Early clinical work explored exactly that.[6] A licensed version called afamelanotide eventually became a prescription treatment for a rare light-sensitivity disease called erythropoietic protoporphyria.[3]

However, research also flagged concerns. Studies noted that Melanotan I can activate dysplastic (abnormal) moles, which is a meaningful safety signal.[3] Surveys of people using it outside clinical settings showed widespread unregulated use purchased online.[4][5]

Quick Comparison

  • Primary research focus: PT-141 → sexual dysfunction | Melanotan I → skin tanning and pigmentation
  • Peptide shape: PT-141 is cyclic | Melanotan I is linear
  • Main receptors targeted: PT-141 targets MC3R and MC4R (brain) | Melanotan I targets MC1R (skin cells)
  • Clinical trial history: PT-141 reached Phase IIb/III planning[1] | Melanotan I led to an approved drug (afamelanotide)[6]
  • Key research concern: PT-141 — nausea and blood pressure changes[2] | Melanotan I — mole activation, unregulated market[3][5]
  • Typical study route: PT-141 was tested as a nasal spray and injection[1] | Melanotan I was tested as a subcutaneous injection[6]

How Research Dosing Differs

In clinical trials, PT-141 was studied at doses ranging roughly from 0.3 mg up to around 10 mg, delivered by nasal spray in earlier studies and by subcutaneous injection in later work.[1][6] Researchers carefully titrated doses to balance effect against side effects like nausea.

Melanotan I research used subcutaneous injections, often in the range of 0.16 mg per kilogram of body weight, given over extended periods to build up pigmentation.[6] Because the goal was gradual skin change rather than an acute response, dosing schedules were typically longer and more spread out compared to PT-141 protocols.

Want to explore these numbers in more detail? Our calculator can help you map out dosing figures from published studies in a clear format.

How to Choose What to Read About

The right literature depends on your research interest. Ask yourself one simple question: what biological process am I curious about?

If you are reading about sexual function, arousal pathways, or central nervous system melanocortin signaling, the PT-141 literature is the richer starting point. The Palatin clinical program generated a solid body of peer-reviewed work on safety, dosing, and mechanism.[1][2]

If you are interested in skin pigmentation, photoprotection, or melanocyte biology, Melanotan I's research trail leads further. Just be aware that this literature also includes important cautions about mole changes and the well-documented underground market for unregulated versions of the peptide.[3][4][5]

Either way, always trace citations back to peer-reviewed sources. Both peptides have attracted significant unregulated use, which means a lot of anecdotal online information exists that does not reflect actual clinical research.[5]

The Bottom Line

PT-141 and Melanotan I are related molecules with genuinely different research stories. They share a common origin in melanocortin science[6] but diverged into separate fields — one pointing toward the brain and sexual health, the other toward the skin and pigmentation. Understanding that distinction is the first step to reading the research intelligently.

Sources

  1. PT-141 Palatin. — Current opinion in investigational drugs (London, England : 2000), 2004. PMID 15134289.
  2. Bremelanotide. — , 2006. PMID 31369224.
  3. [Undesirable pigmentation]. — Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete, 2015. PMID 26315100.
  4. Use of melanotan I and II in the general population. — BMJ (Clinical research ed.), 2009. PMID 19224885.
  5. A glimpse into the underground market of melanotan. — Dermatology online journal, 2018. PMID 30142729.
  6. Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization. — Peptides, 2006. PMID 16412534.
See the dosage chart — PT-141
A melanocortin-receptor agonist studied for sexual function.
PT-141

FAQ

Are PT-141 and Melanotan I the same thing?
No. They are related peptides from the same melanocortin family, but they have different structures and different research applications. PT-141 is a cyclic peptide studied for sexual dysfunction, while Melanotan I is a linear peptide studied for skin tanning and pigmentation. Researchers developed them separately for distinct purposes, and their clinical trial histories reflect those differences.[6]
What receptors do these peptides target in research?
PT-141 primarily targets MC3R and MC4R receptors, which are found in the brain and are linked to sexual arousal and appetite regulation. Melanotan I mainly targets MC1R receptors on skin cells, which trigger melanin production and tanning. This receptor difference explains why the two peptides have such different effects despite being chemically related.[6]
Why is Melanotan I considered risky in research literature?
Studies have flagged two main concerns. First, research found that Melanotan I can activate dysplastic nevi — abnormal moles that could become dangerous.[3] Second, surveys show it is widely purchased through unregulated online markets, meaning users outside clinical trials have no quality control or medical oversight.[4][5] These concerns appear consistently in the peer-reviewed literature.
Where can I find research dosing charts for both peptides?
You can explore published study dosing figures for both peptides on their dedicated pages. Visit the PT-141 dosing chart at /charts/pt-141 or the Melanotan I chart at /charts/melanotan-1. Our /calculator tool can also help you work through dose-per-weight figures drawn from clinical study data in a straightforward, easy-to-read format.
For research and educational use only. Not medical advice.